Early treatment of high‐risk chronic lymphocytic leukemia with alemtuzumab and rituximab

Abstract

The therapy regimen used was safe and effective for early treatment of patients with high-risk CLL. Further studies will be required to determine whether this early treatment strategy decreases morbidity and mortality for high-risk CLL.